Overview

Lumos Pharma, based in Austin, Texas, is focused on developing novel therapies for patients with unmet medical needs in rare and neglected diseases. Lumos Pharma is a proud awardee of the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. The TRND program collaborates with biotechnology companies in the development of early stage technologies that show promise for the treatment of rare diseases. The TRND program provides in-kind scientific and financial support for the preclinical program to allow for the commencement of clinical trials in human subjects.

Lumos Pharma’s lead compound, LUM001, is a novel treatment for the rare disease, Creatine Transporter Deficiency (CTD). CTD is a relatively new and rare disorder, initially described in 2001, and is thought to be the second most common cause of X-linked intellectual disability and developmental delay after Fragile X Syndrome. The inability to transport creatine can lead to intellectual disability, developmental delay,expressive speech deficits, autistic behaviors, and seizures. Many boys are misdiagnosed with autism due to the clinical presentation. LUM001 has been granted orphan status in the US and is in preclinical development in partnership with scientists at the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, through its Therapeutic for Rare and Neglected Diseases program. This NCATS collaboration has helped advance the lead molecule LUM001 as a clinical candidate by generating the data needed to file an investigational new drug application with the Food and Drug Administration. Additionally, Lumos Pharma has partnered with Key Opinion Leaders in the field in conducting a preclinical and clinical development program to evaluate the safety and efficacy of its promising drug candidate for the treatment of CTD.

TRANSFORMING LIVES WITH RARE FOCUS.

MANAGEMENT

Lumos Pharma is led by an experienced management team with longstanding experience in the development and commercialization of therapies in the rare disease space.

Rick Hawkins

President & CEO

Rick Hawkins is Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees. Pharmaco offered a full range…

READ MORE

David M. Weiner, M.D.

Chief Medical Officer

Dave Weiner is Chief Medical Officer of Lumos Pharma. Dr. Weiner has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease.  He started his career at ACADIA Pharmaceuticals, where, over a ten-year…

READ MORE

John C. McKew, Ph.D.

Chief Scientific Officer

John McKew is Chief Scientific Officer of Lumos Pharma.  Dr. McKew most recently served as Vice President of Research for a biotechnology company called aTyr Pharma. There he was responsible for the leading the research organization aimed at…

READ MORE

Robert J. Davis, Pharm.D.

Executive Vice President, Clinical Operations

Bob Davis is Executive Vice President, Clinical Operations of Lumos Pharma. Dr. Davis has over 30 years of Drug Development experience and also has extensive regulatory experience having worked with the FDA, EU and Koseisho in Japan. He served as Chief…

READ MORE

Carol A. Dutch, MIEM/MBA

Senior Director, Patient Engagement

Carol A. Dutch is Senior Director, Patient Engagement at Lumos Pharma.  Over the course of her 25-year career, Ms. Dutch has led successful global launches of ultra-rare products and developed innovative awareness programs, partnering with professional societies and…

READ MORE

DEVELOPMENT

Minh-Ha T. Do, Ph.D.

Director of Pre-Clinical Innovation

Minh-Ha Do is Director of Pre-Clinical Innovation at Lumos Pharma.  Dr. Do previously played dual roles as Program Scientific Lead and Associate Director of Physiology at a biotechnology company called aTyr Pharma.  There, she was…

READ MORE

Aleksandra Bruchey, Ph.D.

Senior Project Manager

Alex Bruchey is Senior Project Manager at Lumos Pharma. Dr. Bruchey started her career in neuroscience research over 15 years ago at Vanderbilt University. She earned her doctorate degree from the University of Texas at Austin, where she…

READ MORE

Chris Bemben, MBA, PMP

Senior Manager, CMC & Nonclinical

Chris Bemben is Senior Manager, CMC & Nonclinical at Lumos Pharma. Mr. Bemben has significant experience in drug discovery and development. He held positions of increasing responsibility as a research scientist at Southwest Research Institute from 2008…

READ MORE

Rosemary French, MBA

Business Strategist

Rosemary French is Business Strategist at Lumos Pharma, and has expertise in business development, patent licensing and international partnerships.  Prior to joining Lumos, Ms. French played a key role in connecting international biotech startups to…

READ MORE

BOARD OF DIRECTORS

G. Gilbert Cloyd

Chairman

G. Gilbert Cloyd, retired Chief Technology Officer of Procter & Gamble, was born in East Cleveland, Ohio. He attended The Ohio State University and received his Doctor of Veterinary Medicine degree in 1969. Following graduation, he…

READ MORE

Rick Hawkins

President & CEO

Rick Hawkins is Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees. Pharmaco offered a full range…

READ MORE

Michele Park

Clarus Funds

Michele Park, PhD, serves as a Partner at Clarus.  Dr. Park joined Clarus in 2006 with five years of sell-side equity research experience covering the biotechnology sector. From 2002-2005, Dr. Park was a research analyst…

READ MORE

Cameron Wheeler

Deerfield Management

Cameron is a Principal on the Private Transactions team at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years,…

READ MORE

Ed Mathers

NEA

Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and…

READ MORE

Kevin Lalande

Santé Ventures

Kevin Lalande is a Founding Partner of Santé Ventures, an early-stage life science and healthcare venture capital company based in Austin, Texas. Prior to Santé, Kevin spent seven years with Austin Ventures, a prominent venture firm with…

READ MORE

Jon S. Saxe

Independent

Mr. Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (NASDAQ:VTGN) and SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and private companies Arbor Vita, Arcuo Medical, Armetheon, Cancer Prevention Pharmaceuticals, …

READ MORE

Emmanuel Lacroix

Board Observer

Emmanuel Lacroix is currently Senior Director Global Business Development at UCB, a global biopharmaceutical company, where he has responsibility for partnering and product licensing/acquisitions in Neurology (including with respect to rare neurological conditions). Previously in Sales &…

READ MORE

Emmett Cunningham

Board Observer

Dr. Cunningham joined Clarus Funds in 2006 with more than 20 years experience in the biomedical and biopharmaceutical sectors.  He is currently a Partner at Clarus.  Prior to joining Clarus, Dr. Cunningham was the Senior Vice…

READ MORE

Robert Heft

Independent

Dr Robert Heft served as President, Chief Executive Officer, and member of the Board of Directors of Enobia Pharma Inc. (Montreal, Quebec) from 2005-2012. In February 2012, Dr Heft sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale of a…

READ MORE

SCIENTIFIC ADVISORY BOARD

Gajja Salomons

Professor of Molecular Biology of Neurometabolic disorders VUMedical Center, Netherlands

READ MORE

Brian Schreiber

Chief Medical Officer, Sigma-Tau Pharmaceuticals

READ MORE

Nicola Longo

Chief, Division of Medical Genetics, Department of Pediatrics University of Utah

READ MORE

OUR OFFICES

LUMOS PHARMA
4200 Marathon Blvd., Suite 200
Austin, Texas 78756
(512) 215-2630